Stacey Kelly, APRN
Nurse Practitioner · Jacksonville, FLNPI 1881671634
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $14,467 of the $21,872 with a category attached, or 66.1%. 40 manufacturers reported payments, led by Dexcom, Inc. at 32.9% of the total. Reporting peaked in 2023 at $8,743 and has fallen 65.7% since, to $2,997 in 2025. Among nurse practitioner clinicians in FL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 562 payments — averaging $38.92 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Dexcom, Inc.$7K
- Abbott$3K
- Medtronic$2K
- Novo Nordisk$2K
- Lilly USA, LLC$1K
- Insulet Corporation$1K
- plus $6K from 34 others
What the payments were for
- Speaking & faculty fees$6,00627%
- Travel & lodging$1,2616%
- Food & beverage$14,46766%
- Education$200%
- Gifts$1191%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Dexcom, Inc. | 20 | $7,187 |
| Abbott | 97 | $2,560 |
| Medtronic | 22 | $1,859 |
| Novo Nordisk | 93 | $1,824 |
| Lilly USA, LLC | 53 | $1,293 |
| Insulet Corporation | 37 | $1,023 |
| Amgen(2 entities) | 27 | $785 |
| Xeris Pharmaceuticals, Inc. | 33 | $696 |
| Corcept Therapeutics | 28 | $677 |
| Mannkind Corporation | 10 | $591 |
| Bayer | 20 | $430 |
| Boehringer Ingelheim | 19 | $409 |
| BETA Bionics, Inc. | 8 | $333 |
| Sanofi-aventis U.S. LLC | 17 | $329 |
| Cequr Corporation | 2 | $226 |
| Tandem Diabetes Care, Inc. | 9 | $218 |
| Ascendis Pharma Endocrinology Inc | 3 | $161 |
| IBSA Pharma Inc. | 10 | $159 |
| Sequel Med Tech, LLC | 3 | $152 |
| Radius Health, Inc. | 6 | $131 |
| AstraZeneca(2 entities) | 6 | $115 |
| AbbVie | 6 | $82 |
| Zealand Pharma US, Inc. | 3 | $71 |
| Recordati_rare_diseases_inc. | 3 | $61 |
| Clarus Therapeutics Inc. | 5 | $60 |
| Amneal Pharmaceuticals LLC | 3 | $49 |
| EUSA Pharma (US) LLC | 2 | $45 |
| Novartis | 2 | $43 |
| Merck | 2 | $42 |
| Averitas Pharma Inc. | 2 | $42 |
| Globus Medical | 2 | $36 |
| Sumitomo Pharma America, Inc. | 1 | $26 |
| Neurocrine Biosciences, Inc. | 1 | $25 |
| Boston Scientific | 1 | $25 |
| Rhythm Pharmaceuticals, Inc. | 1 | $24 |
| GRT US Holding, Inc. | 1 | $23 |
| Lifescan, Inc. | 1 | $16 |
| Almatica Pharma LLC | 1 | $16 |
| Kyowa Kirin, Inc. | 1 | $14 |
| Endo Pharmaceuticals Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- DEXCOM G7 GSS (161)$5,566
- MINIMED 780G$1,445
- DEXCOM G6 TRANSMITTER$1,339
- Omnipod$512
- FreeStyle Libre 2$468
- iLet Bionic Pancreas$385
- Ozempic$369
- AFREZZA$307
- FREESTYLE LIBRE 3$252
- RYBELSUS$245
- CeQur Simplicity$178
- TEPEZZA$150
- iLet Insulin Infusion Kit Inset$128
- iLet Insulin Infusion Kit Contact Detach$128
- Yorvipath$125
- GVOKE PFS$125
- Kerendia$125
- Repatha$124
- JARDIANCE$123
- MOUNJARO$123
How this compares
$21,872 in reported general payments places this provider in the 95th percentile of 8,290 nurse practitioner providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 274 | $427,584 |
| JardianceEmpagliflozin | 151 | $172,633 |
| MounjaroTirzepatide | 55 | $68,647 |
| Tresiba Flextouch U-100Insulin Degludec | 100 | $66,970 |
| Omnipod Dash Pods (Gen 4)Insulin Pump Cart,cont Inf,bt | 41 | $62,682 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 55 | $59,385 |
| RybelsusSemaglutide | 37 | $52,294 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 33 | $44,531 |
| FarxigaDapagliflozin Propanediol | 31 | $38,407 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 49 | $32,782 |
| ProliaDenosumab | 18 | $31,784 |
| Novolog FlexpenInsulin Aspart | 91 | $30,005 |
| Tresiba Flextouch U-200Insulin Degludec | 26 | $27,239 |
| JanuviaSitagliptin Phosphate | 32 | $27,088 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 183 | $25,111 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus, Novolog | $1,824 | $499,460368 claims |
| Boehringer IngelheimJardiance, Tradjenta | $409 | $192,769170 claims |
| Lilly USA, LLCMounjaro, Trulicity, Humalog, Insulin Lispro | $1,293 | $107,206131 claims |
| AstraZenecaFarxiga | $115 | $38,40731 claims |
| AmgenProlia | $785 | $31,78418 claims |
| MerckJanuvia | $42 | $27,08832 claims |
| AbbVieSynthroid | $82 | $4,23871 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $49 | $2,830331 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 8,290 nurse practitioner providers in Florida.
Other nurse practitioner in Jacksonville
- Mary FarrJacksonville$66K
- Jean Sheridan-YoungJacksonville$22K
- Jolanta BaginskiClearwater$494K
- Adissa PerezWinter Park$370K
- April WessonTampa$342K
- Margarita FernandezMiami$311K
- Stephanie SimmermanNaples$283K
- Claudette WalkerPonte Vedra Beach$271K
- Lisa NodzonTampa$246K
- Ashima BahlTampa$226K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.